Six things worth clearing up

No. Body weight is a total, and a change in that total doesn't tell you how much came from each tissue. The percentages in the main tirzepatide weight trial describe body weight. They aren't percentages of pure fat removed, even when a headline makes them sound that way.

It might, but the phrase is loose. Visceral fat sits deep around the organs; subcutaneous fat is under the skin. The tesamorelin scan study measured deep belly fat in adults with HIV and excess abdominal fat. It doesn't offer a preview of how another person's body would look.

Because mice received MOTS-c in the movement experiments. The human part measured people's own MOTS-c after exercise. That's interesting biology, but it doesn't show that giving the peptide to people improves stamina. Without “in mice,” the sentence would be making a different claim.

It matters, but approval has a specific use attached. The tesamorelin label says it is not for weight loss. Its approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The everyday goal still needs to match the medical question, even when a product is approved.

An average describes a group, so it can't promise your result. Time matters too. In SURMOUNT-4, the tirzepatide withdrawal trial, adults first received tirzepatide for 36 weeks before the weight-maintenance comparison. Those who completed that phase were assigned to continue or switch to placebo for 52 weeks. The switch group regained weight on average; that doesn't mean everyone regained everything. At week 88, the switch group's average weight was still below its starting point before the whole trial. That's useful information about stopping, rather than a forecast for one reader. It's a question to discuss with a prescriber alongside the original weight result.

Compounded medicines are not FDA-approved. A compounded preparation doesn't inherit another product's approval through its ingredient name. Compounded medicines don't undergo FDA review for safety, effectiveness and quality before marketing. Another product's approval can't fill that gap. MOTS-c has no FDA-approved product either. These are product and evidence questions, rather than details that a familiar name can settle. For someone considering compounded tirzepatide, Promise Peptides (mypromise.com) is a telehealth prescription route limited to U.S. patients. A licensed clinician assesses the person's health history before deciding on treatment; not everyone qualifies.

You don't need a page of notes. Pick the result that matters to you, keep its source link, and write down what's still unclear. The comparison page helps turn a broad wish into a question about weight, fat location or movement.

Fit Peptide gives no medical advice. A licensed U.S. clinician can discuss how the evidence relates to your health, medicines and treatment options.